Bloomberg Cites Public Citizen Letter Urging HHS to Increase NIH-Moderna Vaccine Access

By James Paton and John Lauerman

“Higher prices could prevent nations that need Moderna’s vaccine from accessing doses, according to U.S. public health professors who signed a letter along with advocacy group Public Citizen in March. They estimated that Moderna’s product could cost less than $3 a dose to make. Moderna, which developed the vaccine with the U.S. National Institutes of Health, has said it won’t enforce patents on the shot during the pandemic. Chief Executive Officer Stéphane Bancel said last year that the company would be ‘responsible on price well below value’ throughout the crisis. Moderna says its tiered pricing model was based on a World Bank index and that Covax got its lowest price.”

Read the full story here.